This Phase I intervention trial (n=30) conducted by Northwest Therapies Trauma Psilocybin Study (NWTTPS) aims to assess the efficacy and safety of enhanced microdosing of psilocybin in treating chronic illnesses such as Trauma, PTSD, Chronic Depression, MS, HIV, and SARS-CoV-2 Long Haulers Syndrome.
The trial utilises non-synthesized psilocybin, administered at enhanced microdose levels (ranging from 0.15g to 0.33g) every other day for 5 days, followed by a maintenance dose of 1 gram to 1.5 grams monthly for 8 weeks. The study hypothesises that psilocybin microdosing could help alleviate symptoms associated with these chronic conditions by rerouting neural pathways and reducing ruminating neurotransmitters.
Patients will work closely with a team including a Psychiatrist, LCPC Therapist, and a Plant Medicine On-Boarding Provider.
The primary outcome measures include the Global Assessment of Functioning (GAF) score and the Brief Addiction Monitor (BAM) score, assessed monthly by the team. Secondary outcome measures include the Posttraumatic Stress Disorder Checklist-5 (PCL-5) score.
The study is set to commence in September 2023 and is estimated to be completed by October 2025.
Trial Details
The on-boarding of unregulatable trauma in the United States has reached 20%, which is 1/5 of the population. A population of this magnitude, by definition has now reached an epidemic classification. The population with chronic illness as stated: PTSD, Chronic Depression, MS, HIV, and SARS-CoV-2- Long Haulers Syndrome. These chronic conditions/illnesses many lead to death and are often the cause or perpetuate unregulated trauma and create an unstable population. Psychiatrists have testified before congress that the SSSRI medications are not fully functional cures and are not working for patients. Enchanced Psilocybin micro-dosing at the levels of 0.15g. ranging to 0.33g. every other day an 0.50g. for monthly maintenance of neural pathway production is proving to shave back the highjacked nervous system, thus stopping or rerouting the ruminating neurotransmitters, by rerouting thru new neural pathways. The body has a additional natural pathway in place then to decrease/stop these thoughts by have open pathways to process the thought differently. Serotonin is a neurotransmitter and which is the most famous of all the neurotransmitters. Serotonin is very similar in its compound structure to the plant medicine family of psilocybin, serotonin and psilocybin work very similarly with the 5h2A receptor in the human cortex ( the outer cortex of the brain ). Enhanced Microdosing of psilocybin at the levels of 0.15 to 0.33 and of 1 gram to 1.5 grams monthly for maintenance of the newly opened neural pathways is postulated to be a mental health game changer. Psilocybin helps shave back the highjacked nervous system which is a condition known as the diagnosis (SSD) Somatic Symptom Disorder. This research is believed accurate by proof on previous studies to process the subconscious held in the subconscious and shave back the somatic feelings resulting from the trauma of the individuals who have on-boarded chronic disease(s) of Trauma,PTSD, Unregulated Chronic Depression, MS, Cancer, HIV, and SARS-CoV-2- Long Haulers Syndrome.Trial Number NCT05042466